1. Figure 1. Rate of PDR in infants according to ARV exposure
Figure 1. Rate of PDR in infants according to ARV exposure. (a) Proportion of cases with single and multi-class ...
Figure 1. Rate of PDR in infants according to ARV exposure. (a) Proportion of cases with single and multi-class resistance to PIs, NRTIs and NNRTIs in all infants studied, divided by ARV exposure (any ARV exposure versus no ARV exposure). (b) Proportion of cases with different ARV exposures carrying single and multi-class resistance to PIs, NRTIs and NNRTIs.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
J Antimicrob Chemother, Volume 74, Issue 3, 05 December 2018, Pages 722–730,
The content of this slide may be subject to copyright: please see the slide notes for details.

2. Figure 2. Frequency of DRMs and predicted level of HIVDR
Figure 2. Frequency of DRMs and predicted level of HIVDR. (a) Proportion of individual DRMs in ARV-exposed and ...
Figure 2. Frequency of DRMs and predicted level of HIVDR. (a) Proportion of individual DRMs in ARV-exposed and ARV-unexposed HIV-1-infected newborns. (b) Predicted level of HIVDR among the 34 infants with at least one DRM before starting first-line ART. (c) Predicted level of HIVDR among seven ARV-naive infants with at least one DRM before starting first-line ART. (d) Predicted level of HIVDR among the 27 infants with at least one DRM before starting first-line ART. Stanford University HIVdb Program was used to predict the level of HIVDR, using PR-RT sequences as input. NVP, nevirapine; EFV, efavirenz; ETV, etravirine; RPV, rilpivirine, 3TC, lamivudine; ABC, abacavir; ZDV, zidovudine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; ATV, atazanavir; DRV, darunavir; LPV, lopinavir/r, boosted with ritonavir.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
J Antimicrob Chemother, Volume 74, Issue 3, 05 December 2018, Pages 722–730,
The content of this slide may be subject to copyright: please see the slide notes for details.